Surrozen Submits IND for SZN-8141, Stock Soars 98%
SRZN has more than doubled off its 52-week low of $11.39 on elevated volume (26× avg).
Summary
Surrozen submitted an Investigational New Drug application to the FDA for SZN-8141, a dual-mechanism therapy for diabetic macular edema. The company plans a Phase 1b/2a DUET trial with enrollment starting late 2026 and initial data expected in H2 2027. Preclinical data showed SZN-8141 outperformed single-agent Wnt or anti-VEGF treatments in reducing neovascularization and vascular leakage. The stock jumped 98.45% to $32.07 on the news, reflecting strong investor enthusiasm for the novel approach. With $102 million in cash as of June 30, the company has runway to advance the program. Key upcoming milestones include trial initiation and initial clinical results in 2027.
At the time of this announcement, SRZN was trading at $31.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $189.9M. The 52-week trading range was $11.39 to $35.86. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.